Arcus Biosciences (Arcus Biosciences) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of May. 31, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Arcus Biosciences EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Arcus Biosciences's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.

Competitive Comparison of Arcus Biosciences's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Biotechnology subindustry, Arcus Biosciences's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arcus Biosciences's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcus Biosciences's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where Arcus Biosciences's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.

Arcus Biosciences (NYSE:RCUS) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Arcus Biosciences EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of Arcus Biosciences's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

Arcus Biosciences (Arcus Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcus Biosciences Inc (NYSE:RCUS) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Comparable Companies

Traded in Other Exchanges

N/A

Address

3928 Point Eden Way, Hayward, CA, USA, 94545

Website

https://www.arcusbio.com

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies.

Executives

Goeltz Ii Robert C.	officer: Chief Financial Officer	343 OYSTER POINT BLVD, SUITE 100, SOUTH SAN FRANCISCO CA 94080
Juan C. Jaen	director, 10 percent owner, officer: President	850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043
Jennifer Jarrett	officer: See Remarks	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Alexander Azoy	officer: Chief Accounting Officer	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Gilead Sciences Inc	10 percent owner	333 LAKESIDE DR, FOSTER CITY CA 94404
Terry J Rosen	director, 10 percent owner, officer: Chief Executive Officer	C/O TULARK INC, TWO CORP DRIVE S, SAN FRANCISCO CA 94080
Carolyn C. Tang	officer: General Counsel	3928 POINT EDEN WAY, HAYWARD CA 94545
Dimitry Sa Nuyten	officer: Chief Medical Officer	740 HEINZ AVENUE, C/O ADURO BIOTECH, INC., BERKELEY CA 94710
Linda Slanec Higgins	director	3610 LOUIS RD., PALO ALTO CA 94303
Nicole Lambert	director	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
William Grossman	officer: Chief Medical Officer	C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Yasunori Kaneko	director, 10 percent owner	509 ROEHAMPTON, HILLS BOROUGH CA 94010
Kathryn E Falberg	director	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Michael Quigley	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Andrew J Perlman	director	618 MIRADA AVE, STANFORD CA 94305